ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO172

Autoantibodies to Apolipoprotein A-1 as Independent Predictors of Cardiovascular Mortality in Renal Transplant Recipients

Session Information

Category: Transplantation

  • 1802 Transplantation: Clinical


  • Anderson, Josephine, University Medical Centre Groningen, Groningen, Netherlands
  • Pagano, Sabrina, Geneva University Hospital, Geneva, Switzerland
  • Annema, Wijtske, Geneva University Hospital, Geneva, Switzerland
  • Bakker, Stephan J.L., University Medical Center Groningen, Groningen, Netherlands
  • Vuilleumier, Nicolas, Geneva University Hospital, Geneva, Switzerland
  • Tietge, Uwe Jf, University Medical Center Groningen, Groningen, Netherlands

The aim of this study was to determine i) the prognostic value of autoantibodies against apoA-1 (anti-apoA-1 IgG) for incidence of cardiovascular disease (CVD) specific mortality, all-cause mortality and graft failure in renal transplant recipients (RTR), patients known to have a high CVD burden only partly explained by traditional CVD risk factors, and ii) to delineate the relationship of anti-apoA-1 IgG with HDL functionality.


462 prospectively included RTR were followed for 7.0 years. Baseline anti-apoA-1 IgG were determined and associations with incidence of CVD mortality (n=48), all-cause mortality (n=92) and graft failure (n=39) were tested.


HDL functionality assessed in vitro by measuring anti-oxidative and cholesterol efflux capacity was not associated with anti-apoA-1 IgG levels. Kaplan–Meier analyses demonstrated significant associations of anti-apoA-1 IgG with CVD mortality (log rank test among tertiles: P=0.048). Adjusted Cox regression analysis showed that for each standard deviation increase of log transformed anti-apoA-1 IgG values, there was a 4-fold increase (hazard ratio [HR]: 4.00; 95% confidence interval [95%CI]:1.32-12.11; p=0.01) in risk for CVD mortality and a more than 2-fold increase for all-cause mortality (HR:2.69, 95%CI:1.25-5.83; P=0.01), independent of CVD risk factors, renal and HDL function. The association with all-cause mortality disappeared after excluding cases of CVD specific mortality. The sensitivity, specificity, positive predictive value, and negative predictive value of anti-apoA-1 positivity for CVD mortality were 18.0%, 89.3%, 17.0%, and 90.0%, respectively.


In conclusion, this prospective study demonstrates that in RTR, anti-apoA-1 IgG are independent predictors of CVD mortality. In RTR, anti-apoA-1 IgG are not associated with HDL functionality.